Focused ultrasound is an MRI-guided procedure that deliberately creates a small, permanent thermal lesion in a precisely selected brain target. In the United States, the FDA-cleared indication depends on that target: unilateral thalamotomy is used for medication-refractory tremor-dominant Parkinson’s disease, while pallidothalamic tractotomy (and, under applicable labeling, pallidotomy) is used for advanced idiopathic Parkinson’s disease with medication-refractory moderate-to-severe motor complications. It is not a cure, does not treat every Parkinson’s symptom, and is not suitable for everyone.
What focused ultrasound treats in Parkinson’s disease
“Focused ultrasound for Parkinson’s” describes more than one treatment. The brain target, the symptom being treated, and the applicable FDA indication determine what the procedure is intended to do. A clinician should identify those three points before discussing likely benefit or risk.
As an Amazon Associate I earn from qualifying purchases.
| FDA-described pathway in the United States | Brain target and procedure | Who it is intended for | Primary problem addressed |
|---|---|---|---|
| Tremor-dominant Parkinson’s disease | Unilateral thalamotomy of the ventral intermediate (VIM) target | Adults age 30 or older with specialist-confirmed tremor-dominant Parkinson’s, disabling tremor despite optimal medication, or medication intolerance for other cardinal symptoms | Disabling Parkinsonian tremor, generally on one side |
| Advanced idiopathic Parkinson’s disease with motor complications | Unilateral pallidothalamic tractotomy; applicable labeling also describes pallidotomy | Adults age 30 or older with medication-refractory, moderate-to-severe motor complications and a target that can be identified and safely reached for thermal ablation | Medication-refractory motor complications rather than tremor alone |
The FDA’s PMA supplement S037, decided July 3, 2025, also describes a staged procedure on the opposite side for pallidothalamic tractotomy. The second side may be treated at least six months after the first when the contralateral motor complications remain medication-refractory and have not previously been treated. This does not mean that everyone should have both sides treated or that a bilateral procedure controls the progression of Parkinson’s disease.
A lesion in one circuit can improve the symptom linked to that circuit while leaving other problems—such as gait difficulty, balance impairment, speech changes, cognitive symptoms, or sensory complaints—unchanged. Parkinson’s is a progressive, multisystem disease; focused ultrasound treats a selected symptom pathway, not the underlying disease as a whole.
#1 Best Overall
- Portable Joint Care Device: This compact massager hand-held is a simple personal-care tool for non-invasive joint care and daily muscle comfort. Use it at home, in the office, after physical activity, or while traveling.
- Focused Comfort: Designed for targeted use around the knees, elbows, wrists, ankles, neck, shoulders, back, hands, and feet. This back massager handheld supports convenient everyday comfort.
- User-Friendly Design: Choose low, medium, or high intensity to match your preferred comfort level. This hand held back massager comes with an ergonomic grip and simple touch control which makes sessions easy to manage for relaxation and everyday wellness.
- Travel-Ready Convenience: Lightweight and easy to store, this body massager handheld design is made for simple handling and daily application. The corded design uses the included power adapter without requiring battery recharging.
- Everyday Personal Care: This compact massager handheld device provides convenient joint-area comfort and muscle relaxation. It is designed as a simpler alternative to bulky massage devices and is not an ultrasound device.
Am I a candidate?
Candidacy is an individualized decision made with a movement-disorders neurologist and the treating focused-ultrasound team. Having a Parkinson’s diagnosis, even with severe symptoms, does not by itself establish eligibility. The team must confirm the indication, determine whether the relevant target is visible and reachable, and decide whether you can safely undergo MRI-guided treatment.
Clinical questions the team will assess
- Is the diagnosis idiopathic Parkinson’s disease, and does your symptom pattern match the specific FDA pathway?
- Which symptom is most disabling: tremor, dyskinesia, rigidity, “off” periods, or another motor complication?
- Have appropriate medications been tried at effective doses, and are symptoms still disabling or medication effects intolerable?
- Are the complications moderate to severe and sufficiently consistent to justify an irreversible lesion?
- Can you remain awake, still, and able to communicate sensations during targeting and treatment?
- Is your general health adequate for prolonged MRI positioning and the procedure itself?
Imaging and skull screening
Planning uses MRI and CT. MRI shows the brain and helps the team plan and monitor treatment; CT evaluates skull shape and density because the ultrasound beam must pass through the skull and converge accurately. The prescriber information describes an overall skull-density-ratio threshold and requires that the target be visible and accessible for thermal ablation. A skull that attenuates or distorts the beam may make treatment unsafe or technically impractical.
You also need to tolerate the MRI environment and any required positioning. Tell the center about metal implants, devices, prior cranial procedures, substantial scalp scarring, and any problem that could prevent you from lying still. The team—not a screening checklist alone—determines whether an implant is MRI-compatible under the scanner’s conditions.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Health and medication screening
Current FDA prescriber information identifies several concerns that can exclude treatment or require additional evaluation:
- Standard MRI contraindications, including certain non-MRI-compatible implants or foreign metal.
- Pregnancy.
- Advanced kidney disease or dialysis, depending on the MRI protocol and contrast requirements.
- Unstable cardiac disease or severe, uncontrolled hypertension.
- A bleeding disorder, coagulopathy, recent cerebrovascular disease, or a history that raises hemorrhage risk.
- Anticoagulant or other hemorrhage-risk medicines taken within the period specified by the treating protocol, including the one-month concern identified in labeling.
- Brain tumors or other structural conditions that affect safe targeting.
- Substance-abuse behaviors that could compromise treatment or follow-up.
- Unstable psychiatric illness or uncontrolled depressive symptoms.
- Inability to tolerate prolonged stationary positioning or to communicate during treatment.
The patient guide also advises discussing seizure history, prior stroke or brain bleed, previous deep brain stimulation, bleeding conditions, metal implants, and general MRI tolerance. That guide reflects an earlier tremor-dominant labeling context, so the current prescriber information and your clinicians’ review control the final decision.
Rank #2
- Light Weight Easy To Oprate
What happens during the procedure?
- Pre-procedure evaluation. The movement-disorders specialist confirms the symptom target, medication history, examination findings, and alternatives. MRI and CT are reviewed for target visibility and skull transmission.
- Positioning in the MRI system. The procedure takes place in an MRI scanner. The equipment supports anatomical planning, real-time guidance, and temperature monitoring.
- Low-energy test sonications. The team uses test exposures to verify that the beam is reaching the intended location and to ask what you feel. You must be able to report sensations and remain still.
- Therapeutic heating. Ultrasound energy is focused repeatedly on the selected target. The energy raises tissue temperature enough to destroy a small area, and MRI thermometry helps the team monitor the thermal dose.
- Neurological checks. The clinicians assess the intended symptom and watch for unwanted sensations, weakness, speech changes, imbalance, or other neurological effects before completing treatment.
- Observation and follow-up planning. Your center will provide instructions for observation, medicines, activity, driving, follow-up visits, and symptoms that require urgent contact.
The FDA-hosted Exablate Neuro Patient Guide USA explains the physical principle this way: “Ultrasound is a form of sound energy that passes through skin, muscle, fat, and bone without the need for incisions, electronic leads, or inserted probes.”
Is focused ultrasound really noninvasive?
It is noninvasive in the procedural sense: there is no skin incision, inserted probe, or implanted stimulation lead. It is not non-ablative. The treatment intentionally heats and destroys brain tissue, creating a permanent lesion. That distinction matters when comparing it with deep brain stimulation (DBS), which places electrodes and a pulse generator but allows stimulation settings to be adjusted after surgery.
Because the lesion is intentional and generally irreversible, the decision should include what happens if the symptom later changes, if the lesion affects an adjacent pathway, or if you eventually need treatment on the other side. The absence of implanted hardware does not mean the procedure is risk-free or automatically easier to reverse.
What benefits can you reasonably expect?
The strongest named Parkinson’s evidence in the supplied clinical record comes from a small, two-center, double-blind, sham-controlled pilot randomized trial published in JAMA Neurology in 2018. It enrolled 27 people with medication-refractory, tremor-dominant Parkinson’s disease: 20 received unilateral focused-ultrasound thalamotomy and seven received a sham procedure. At three months, treated-hand tremor scores improved by a median 62% in the treatment group compared with 22% after sham; the difference between groups was statistically significant.
That 62% figure is not a general success rate. It describes a small, selected population, one symptom (treated-hand tremor), one target (the thalamus), and a three-month assessment. It cannot predict your result, establish the chance of benefit from pallidothalamic tractotomy, or show that all Parkinson’s symptoms will improve. No population-wide probability of benefit, reliable personalized prediction, or comprehensive recovery-time statistic is established by these sources.
Rank #3
- Light Weight Easy To Oprate
Ask the treating center to define the outcome it expects to measure: tremor amplitude, time spent “off,” dyskinesia, rigidity, walking, medication reduction, or quality-of-life scores. A meaningful improvement in one measure may coexist with persistent problems in another.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →What are the risks?
Neurological effects related to the lesion
Risk depends on the target, the exact anatomy, the thermal exposure, and your health. The small tremor trial reported paresthesia (tingling or altered sensation) and ataxia (poor coordination). Two participants developed mild hemiparesis associated with capsular heating, and some sensory or balance effects persisted at follow-up. These historical findings do not provide a current universal percentage for the newer pallidothalamic tractotomy indication.
Possible effects to discuss include weakness, numbness, imbalance, gait worsening, speech or swallowing changes, visual symptoms, or other neurological deficits if heat reaches nearby structures. The relevant question is not whether a center can promise “no risk,” but how it identifies, limits, monitors, and manages risk for your specific target.
Procedure and MRI-related effects
Headache, dizziness, or vertigo related to the MRI and ultrasound environment occurred in the pilot trial and resolved by the end of the procedure. Prolonged positioning can be difficult for people with severe back, neck, respiratory, or movement problems. Tell the team in advance if pain, claustrophobia, or involuntary movements could prevent you from remaining still.
Risks that require urgent instructions
Before leaving, obtain written instructions for urgent contact. Ask specifically what to do for new or worsening weakness, inability to walk, severe imbalance, confusion, speech or swallowing difficulty, severe headache, seizure, fever, or other sudden neurological change. Do not assume that a symptom is an expected temporary effect simply because the procedure was noninvasive.
Free tools Windows power users keep installed
One-click scans. No signup required.
Rank #4
- ♥Ultrasound Therapy for Home Use: Designed for convenient at-home body care, this handheld ultrasound therapy device helps support relaxation and targeted comfort for areas such as the back, shoulders, arms, legs, and other muscles after daily activity or exercise.
- ♥Multiple Pain Relief Functions: Effectively treats shoulder pain, calcific tendonitis, radial/ulnar epicondylitis, trochanteric tendonitis, waist or stern pain, patellar tendonitis, tibial stress syndrome, achillodynia, plantar fasciitis, and supports E‑D therapy
- ♥Portable & Quiet : Compact, lightweight design with low‑noise operation for home, office, gym, spa, or salon. Simple controls make it convenient to use anywhere.
- ♥Customer Support: Please contact us with any product questions or concerns. We are committed to providing helpful support and a positive customer experience.
- ♥Advanced Shockwave Principle: Electromagnetic pressure waves deliver a rapid rise and gradual release of pressure to stimulate deep tissue and promote circulation for improved comfort and mobility
How long is recovery?
There is no single, evidence-based recovery schedule that applies to every indication, target, or patient. The sources describe MRI-guided treatment and prolonged positioning but do not establish a universal same-day discharge rule, return-to-work date, or fixed period for driving restrictions. Some effects may be noticed during treatment, while others evolve as the lesion settles; your center’s protocol is the appropriate source for timing.
Before scheduling, ask for a written plan covering:
- How long observation lasts and whether an overnight stay is possible.
- When you may drive, travel, exercise, work, or resume usual activities.
- Whether Parkinson’s medicines change immediately or only after follow-up assessment.
- When neurological examinations, MRI or other imaging, and movement-disorders visits occur.
- Which symptoms are expected, which are concerning, and whom to call after hours.
- What happens if the desired symptom response is incomplete or an adverse effect appears.
Do not stop Parkinson’s medication on your own. The treated pathway may reduce one complication without replacing medication for other symptoms, and medication changes need clinical supervision.
Focused ultrasound versus DBS and medication
FDA materials identify medication management and DBS among alternatives for Parkinson’s symptom treatment. There is no universal ranking; the right comparison starts with your most disabling symptom and the trade-offs you value.
| Decision axis | Focused ultrasound lesioning | Deep brain stimulation (DBS) | Medication management |
|---|---|---|---|
| What is created? | A deliberately heated, permanent lesion in a selected target; no implanted lead | Implanted electrodes and a pulse generator that deliver adjustable stimulation | No brain lesion or implant; drug effects and side effects are managed over time |
| Adjustability | The lesion is not programmable or reversible | Settings can be adjusted, and hardware can potentially be revised or removed | Doses and schedules can be changed, subject to response and tolerability |
| Laterality | Usually unilateral; staged contralateral pallidothalamic treatment may be considered at least six months later under applicable labeling | May address bilateral symptoms, but requires individualized surgical planning | Systemic treatment can affect symptoms on both sides but may cause systemic adverse effects |
| Eligibility issues | Skull transmission, MRI compatibility, target visibility, health, and ability to communicate and remain still | Surgical fitness, implant considerations, programming follow-up, and hardware-related risks | Organ function, interactions, adverse effects, adherence, and changing disease response |
Use these questions in a consultation:
- Which symptom and brain target does each option address?
- Would treatment be one-sided or bilateral, and what is the plan if the other side later becomes disabling?
- Is an irreversible lesion acceptable, or is future adjustability more important?
- How do MRI requirements, surgery, implants, bleeding risk, and follow-up burden differ for you?
- What experience does the center have with your indication and target?
- How might each option affect future treatment choices?
Unilateral lesioning cannot eliminate the bilateral nature or future progression of Parkinson’s disease. A careful comparison should therefore include long-term flexibility, not only the immediate procedure.
Questions to ask at a consultation
- Which FDA indication applies to me: tremor-dominant thalamotomy or motor-complication pallidothalamic tractotomy?
- What exact target will be treated, and which symptom is the realistic goal?
- What medication trials and assessments document that my symptoms are refractory?
- What did my CT show about skull density and ultrasound transmission?
- What is my individualized risk of weakness, numbness, imbalance, speech change, or gait worsening?
- Will my medicines change before or after treatment?
- What are the observation, driving, travel, and activity rules for this center?
- What is the plan if benefit is partial, delayed, or accompanied by a persistent side effect?
- If the opposite side later needs treatment, what criteria and interval would apply?
Bottom line
Focused ultrasound can be a useful option for carefully selected adults with a specific medication-refractory Parkinson’s problem, but the indication and target determine almost everything that follows. In the United States, unilateral VIM thalamotomy is the tremor-dominant pathway, while pallidothalamic tractotomy is used for advanced motor complications under the applicable FDA labeling. The procedure avoids an incision and implanted lead yet permanently destroys a small area of brain tissue. A movement-disorders specialist, MRI/CT skull screening, and a detailed discussion of irreversible effects, alternatives, and center-specific recovery instructions are essential before deciding.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
